KMT2A and acute myeloid leukemia: KMT2A-rearranged AML is clearly associated with inferior outcomes in several clinical series, including refractory disease, poor PFS and OS, and higher risks of coagulopathy, bleeding, and early death than AML with a normal karyotype [10,27].